KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Change in Inventory (2016 - 2025)

Pacira BioSciences has reported Change in Inventory over the past 16 years, most recently at -$4.8 million for Q4 2025.

  • Quarterly results put Change in Inventory at -$4.8 million for Q4 2025, down 135.9% from a year ago — trailing twelve months through Dec 2025 was $27.6 million (up 31.72% YoY), and the annual figure for FY2025 was $27.6 million, up 31.72%.
  • Change in Inventory for Q4 2025 was -$4.8 million at Pacira BioSciences, down from $9.5 million in the prior quarter.
  • Over the last five years, Change in Inventory for PCRX hit a ceiling of $14.4 million in Q2 2025 and a floor of -$7.6 million in Q1 2024.
  • Median Change in Inventory over the past 5 years was $1.9 million (2021), compared with a mean of $2.9 million.
  • Peak annual rise in Change in Inventory hit 11988.37% in 2022, while the deepest fall reached 567.17% in 2022.
  • Pacira BioSciences' Change in Inventory stood at $1.9 million in 2021, then crashed by 138.54% to -$735000.0 in 2022, then skyrocketed by 1165.71% to $7.8 million in 2023, then soared by 71.29% to $13.4 million in 2024, then plummeted by 135.9% to -$4.8 million in 2025.
  • The last three reported values for Change in Inventory were -$4.8 million (Q4 2025), $9.5 million (Q3 2025), and $14.4 million (Q2 2025) per Business Quant data.